
The first genetic steps towards acute myeloid leukaemia, one of the most aggressive blood cancers, can be taken in childhood or adolescence and then sit quietly for half a century before the disease appears, according to a British study that used stored blood samples as a kind of fossil record.
Researchers from the University of Cambridge and University College London found that in two-thirds of the cases they studied, the first cancer-driving mutation had arisen before the age of 20, more than 50 years ahead of diagnosis. The work, published in Nature, also suggests that the way these mutated cells grow is predictable enough that doctors might one day spot people at highest risk years in advance.
A blood archive collected for a different purpose
The study was made possible by an unusual resource. Between them, around 50,000 women gave a blood sample every year for up to 11 years as part of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), a trial designed to test ovarian cancer screening rather than anything to do with leukaemia, the University of Cambridge said.
The team identified 47 women from the trial who later developed acute myeloid leukaemia (AML), at an average age of 72, and compared their samples with those of 46 women who remained free of blood cancer. Some samples dated back as far as 15 years before diagnosis. Using ultra-sensitive DNA sequencing and mathematical modelling, the scientists estimated when each mutation first appeared and how quickly the affected cells multiplied and competed with healthy blood cells.
Professor Usha Menon of UCL, who led UKCTOCS, said the trial’s serial samples had become “a unique bioresource” and paid tribute to the participants whose generosity made the work possible, UCL reported.
Slow for decades, then rapid
The picture that emerged is one of a very long, slow fuse. After the first mutation, cells carrying it took years to double in number. But each additional cancer-driving mutation sped things up roughly two- to three-fold, so that cells carrying four such mutations were doubling in a matter of weeks.
Crucially, these expanding families of cells, known as clones, grew at a steady and remarkably predictable rate once established, slowing only when they ran out of space or were overtaken by a faster rival. That means a clone’s growth rate measured from just a few blood samples could, in principle, be used to forecast how large it will become years or decades later.
“What surprised us most is how predictable the growth of these clones is,” said Professor Jamie Blundell of Cambridge’s Early Cancer Institute, who led the study. “Once a clone is established, its growth rate today tells you where it will be years, even decades, from now.”
A warning sign hiding in plain sight
Many healthy older adults carry blood cells with mutations also seen in leukaemia, a condition called clonal haematopoiesis, yet only a small fraction ever develop AML. Until now it has been unclear why, because no one had tracked the process year by year before diagnosis.
The study offers one clue. In at least a third of the AML cases, a single clone had come to dominate the blood years before diagnosis, an event the researchers call a “somatic sweep”. No such sweeps were seen in the women who stayed cancer-free. Checking against UK Biobank data, the team found that people with these sweeps faced a greatly increased risk of the disease.
The finding has a practical sting: standard genetic tests often miss such sweeps because a mutation present in almost all of a person’s blood cells can be mistaken for one they inherited.
Why acute myeloid leukaemia is so hard to beat
AML affects around 2,700 people in the UK each year, and only about one in six survive for five years after diagnosis, according to the researchers. It often moves quickly and is difficult to treat, which is why the prospect of intervening long before symptoms appear is so appealing.
Because the clones grow exponentially, the team’s modelling suggests that even modestly slowing a high-risk clone over the decade or more before diagnosis could substantially cut the chance it turns into leukaemia. Testing whether that can be done safely in people identified as high risk is the researchers’ next step.
Dr Caroline Watson, the study’s first author and an honorary consultant haematologist, already sees patients at the Cambridge Clonal Haematopoiesis Clinic at Addenbrooke’s Hospital, which the university describes as the first clinic in Europe focused on leukaemia prevention. She said the findings offered “real hope” of better identifying who is most at risk and pointed to “a window in which prevention could one day be possible”.
The limits
The study is not the final word. It involved a relatively small group, all of them women, who were diagnosed between the ages of 53 and 83, and it did not include samples taken at the moment of diagnosis. In around one in five cases, the expanding mutated cells only became detectable one to two years before diagnosis, suggesting some patients may offer a much shorter warning period.
Even so, the research shows the hidden value of long-running British studies and biobanks, and hints at a future in which leukaemia could be anticipated rather than simply treated. The work was largely funded by UK Research and Innovation and Cancer Research UK. Read more in our Science and Health sections.





























